This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Jark Boettcher: Innovator in Antibody Therapeutics
Introduction
Jark Boettcher is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on innovative solutions for cancer treatment, showcasing his commitment to advancing medical science.
Latest Patents
Jark Boettcher holds a patent for an antagonizing CD73 antibody. This invention relates to novel antagonizing antibodies for CD73, which are crucial for therapeutic applications in cancer diseases. The patent also encompasses nucleic acids encoding such antibody molecules, methods for preparing these antibodies, and host cells capable of expressing them. Additionally, it includes compositions comprising these antibody molecules and their uses in therapeutic contexts.
Career Highlights
Jark Boettcher is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His role involves research and development in the field of antibody therapeutics, where he applies his expertise to create innovative solutions for complex medical challenges.
Collaborations
Throughout his career, Jark has collaborated with esteemed colleagues, including Rajkumar Ganesan and Markus Zettl. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to groundbreaking advancements in the field.
Conclusion
Jark Boettcher's contributions to antibody therapeutics exemplify his dedication to improving cancer treatment. His innovative patent and collaborative efforts position him as a key figure in the biotechnology industry.